🔴 Moderna is trading 4.6% down today after norovirus vaccine setback outweighs Q2 revenue beat

Moderna is trading 4.6% down now at $55.28 as investors focus on a Phase 3 norovirus vaccine setback that overshadowed a second-quarter revenue beat.

• The company reported $145 million in quarterly revenue and reiterated its 2026 guidance, but the norovirus candidate failed to meet early success criteria.
• Broader biotech weakness is adding pressure to the stock, with the XBI down 3.15% in the session.
• The sector-wide decline likely amplified the post-earnings selloff following a sharp rally in the share price on July 30.